Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva + Gemcitabine in Advanced Pancreatic Cancer
NCT02694536Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2006
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erlotinib in pancreatic cancer (PC), sponsored by Roche. Primary endpoint: Percentage of Participants With Adverse Events at 40 months. Started Aug 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02694536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694536.